Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders

Kazuo Tamura, Akio Urabe, Minoru Yoshida, Akihisa Kanamaru, Yoshihisa Kodera, Shinichiro Okamoto, Shigefumi Maesaki, Tohru Masaoka

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The study was conducted as a prospective multicenter trial to evaluate the efficacy and safety of micafungin in patients with invasive fungal infections (IFIs) in hematological disorders. A total of 277 patients was registered, and 197 were assessed for clinical efficacy. The mean dosage and duration of micafungin were 170.7 mg/day and 22.0 days, respectively. The efficacy rates were 87.5% (7/8) for patients with candidiasis, 44.7% (17/38) for probable IFIs, 61.9% (39/63) for possible IFIs and 80.7% (71/88) for those who failed to respond to antibacterials. In patients with febrile neutropenia (below 500 μL), despite broad-spectrum antibacterial treatment over 2 days, 86.3% (44/ 51) of patients had a favourable response to micafungin. The incidence of adverse events related to micafungin was 14.1% (39/277), but most of them were mild and reversible. These data indicate the usefulness of micafungin as a novel therapeutic drug for both empirical and targeted therapy for IFIs.

Original languageEnglish
Pages (from-to)92-100
Number of pages9
JournalLeukemia and Lymphoma
Volume50
Issue number1
DOIs
Publication statusPublished - 2009 Feb 6

Keywords

  • Echinocandin
  • Empirical therapy
  • Febrile neutropenia
  • Fungal infection
  • Hematological disorders
  • Micafungin

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders'. Together they form a unique fingerprint.

  • Cite this